Neuroinvasive flavivirus infections

Reviews in Medical Virology

Volumn 22, Issue 2, 2012, Pages 69-87

  Sips, Gregorius J ^a   Wilschut, Jan ^a   Smit, Jolanda M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; JAPANESE ENCEPHALITIS VACCINE; TICK BORNE ENCEPHALITIS VACCINE; WEST NILE VACCINE;

ANTIVIRAL THERAPY; BRAIN INFECTION; CENTRAL NERVOUS SYSTEM DISEASE; DENGUE; DENGUE VIRUS; FLAVIVIRUS; FLAVIVIRUS INFECTION; HISTOPATHOLOGY; HUMAN; JAPANESE ENCEPHALITIS; JAPANESE ENCEPHALITIS VIRUS; NONHUMAN; PATHOGENESIS; REVIEW; TICK BORNE ENCEPHALITIS; TICK BORNE ENCEPHALITIS FLAVIVIRUS; WEST NILE FEVER; WEST NILE FLAVIVIRUS;

COMMUNICABLE DISEASES, EMERGING; ENCEPHALITIS, VIRAL; FLAVIVIRUS; FLAVIVIRUS INFECTIONS; HUMANS; WORLD HEALTH;

EID: 84858000382     PISSN: 10529276     EISSN: 10991654     Source Type: Journal    
DOI: 10.1002/rmv.712     Document Type: Review

References (160)

1. Morens DM, Folkers GK, Fauci AS. The challenge of emerging and re-emerging infectious diseases. Nature 2004; 430: 242-249. DOI: 10.1038/nature02759
2. Mackenzie JS, Gubler DJ, Petersen LR. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nature Medicine 2004; 10: S98-109. DOI: 10.1038/nm1144
3. Weissenbock H, Hubalek Z, Bakonyi T, et al. Zoonotic mosquito-borne flaviviruses: worldwide presence of agents with proven pathogenicity and potential candidates of future emerging diseases. Veterinary Microbiology 2010; 140: 271-280. DOI: 10.1016/j.vetmic.2009.08.025
4. Dobler G. Zoonotic tick-borne flaviviruses. Veterinary Microbiology 2010; 140: 221-228. DOI: 10.1016/j.vetmic.2009.08.024
5. Gould EA, Solomon T. Pathogenic flaviviruses. Lancet 2008; 371: 500-509. DOI: 10.1016/S0140-6736(08)60238-X
6. Mukhopadhyay S, Kuhn RJ, Rossmann MG. A structural perspective of the flavivirus life cycle. Nature Reviews Microbiology 2005; 3: 13-22. DOI: 10.1038/nrmicro1067
7. Weaver SC, Barrett AD. Transmission cycles, host range, evolution and emergence of arboviral disease. Nature Reviews Microbiology 2004; 2: 789-801. DOI: 10.1038/nrmicro1006
8. McMinn PC. The molecular basis of virulence of the encephalitogenic flaviviruses. Journal of General Virology 1997; 78(Pt 11): 2711-2722.
9. Solomon T. Flavivirus encephalitis. The New England Journal of Medicine 2004; 351: 370-378. DOI: 10.1056/NEJMra030476
10. Varatharaj A. Encephalitis in the clinical spectrum of dengue infection. Neurology India 2010; 58: 585-591. DOI: 10.4103/0028-3886.68655
11. Murthy JM. Neurological complication of dengue infection. Neurology India 2010; 58: 581-584. DOI: 10.4103/0028-3886.68654
12. Solomon T, Dung NM, Vaughn DW, et al. Neurological manifestations of dengue infection. Lancet 2000; 355: 1053-1059. DOI: 10.1016/S0140-6736(00)02036-5
13. Misra UK, Kalita J. Overview: Japanese encephalitis. Progress in Neurobiology 2010; 91: 108-120. DOI: 10.1016/j.pneurobio.2010.01.008
14. Ghosh D, Basu A. Japanese encephalitis-a pathological and clinical perspective. PLoS Neglected Tropical Diseases 2009; 3: e437. DOI: 10.1371/journal.pntd.0000437
15. World Health Organization. [1 February 2011].
16. Gould EA, Solomon T, Mackenzie JS. Does antiviral therapy have a role in the control of Japanese encephalitis? Antiviral Research 2008; 78: 140-149. DOI: 10.1016/j.antiviral.2007.10.005
17. Wilder-Smith A, Halstead SB. Japanese encephalitis: update on vaccines and vaccine recommendations. Current Opinion in Infectious Diseases 2010; 23: 426-431. DOI: 10.1097/QCO.0b013e32833c1d01
18. World Health Organization. WHO position paper on Japanese encephalitis vaccines. WHO Weekly Epidemiological Record 2006; 81: 331-340.
19. Ravi V, Desai AS, Shenoy PK, et al. Persistence of Japanese encephalitis virus in the human nervous system. Journal of Medical Virology 1993; 40: 326-329.
20. Sharma S, Mathur A, Prakash V, et al. Japanese encephalitis virus latency in peripheral blood lymphocytes and recurrence of infection in children. Clinical and Experimental Immunology 1991; 85: 85-89.
21. German AC, Myint KS, Mai NT, et al. A preliminary neuropathological study of Japanese encephalitis in humans and a mouse model. Transactions of the Royal Society of Tropical Medicine and Hygiene 2006; 100: 1135-1145. DOI: 10.1016/j.trstmh.2006.02.008
22. Desai A, Shankar SK, Ravi V, et al. Japanese encephalitis virus antigen in the human brain and its topographic distribution. Acta Neuropathologica 1995; 89: 368-373.
23. Johnson RT, Burke DS, Elwell M, et al. Japanese encephalitis: immunocytochemical studies of viral antigen and inflammatory cells in fatal cases. Annals of Neurology 1985; 18: 567-573. DOI: 10.1002/ana.410180510
24. Ishii T, Matsushita M, Hamada S. Characteristic residual neuropathological features of Japanese B encephalitis. Acta Neuropathologica 1977; 38: 181-186.
25. Zimmerman HM. The pathology of Japanese B encephalitis. American Journal of Pathology 1946; 22: 965-991.
26. Myint KS, Raengsakulrach B, Young GD, et al. Production of lethal infection that resembles fatal human disease by intranasal inoculation of macaques with Japanese encephalitis virus. The American Journal of Tropical Medicine and Hygiene 1999; 60: 338-342.
27. Liu TH, Liang LC, Wang CC, et al. The blood-brain barrier in the cerebrum is the initial site for the Japanese encephalitis virus entering the central nervous system. Journal of Neurovirology 2008; 14: 514-521. DOI: 10.1080/13550280802339643
28. Liou ML, Hsu CY. Japanese encephalitis virus is transported across the cerebral blood vessels by endocytosis in mouse brain. Cell and Tissue Research 1998; 293: 389-394.
29. Hase T, Dubois DR, Summers PL. Comparative study of mouse brains infected with Japanese encephalitis virus by intracerebral or intraperitoneal inoculation. International Journal of Experimental Pathology 1990; 71: 857-869.
30. McMinn PC, Dalgarno L, Weir RC. A comparison of the spread of Murray Valley encephalitis viruses of high or low neuroinvasiveness in the tissues of Swiss mice after peripheral inoculation. Virology 1996; 220: 414-423. DOI: 10.1006/viro.1996.0329
31. Monath TP, Cropp CB, Harrison AK. Mode of entry of a neurotropic arbovirus into the central nervous system. Reinvestigation of an old controversy. Laboratory Investigation 1983; 48: 399-410.
32. Das S, Basu A. Japanese encephalitis virus infects neural progenitor cells and decreases their proliferation. Journal of Neurochemistry 2008; 106: 1624-1636. DOI: 10.1111/j.1471-4159.2008.05511.x
33. Ogata A, Nagashima K, Hall WW, et al. Japanese encephalitis virus neurotropism is dependent on the degree of neuronal maturity. Journal of Virology 1991; 65: 880-886.
34. Das S, Laxminarayana SV, Chandra N, et al. Heat shock protein 70 on Neuro2a cells is a putative receptor for Japanese encephalitis virus. Virology 2009; 385: 47-57. DOI: 10.1016/j.virol.2008.10.025
35. Ghoshal A, Das S, Ghosh S, et al. Proinflammatory mediators released by activated microglia induces neuronal death in Japanese encephalitis. Glia 2007; 55: 483-496. DOI: 10.1002/glia.20474
36. Su HL, Liao CL, Lin YL. Japanese encephalitis virus infection initiates endoplasmic reticulum stress and an unfolded protein response. Journal of Virology 2002; 76: 4162-4171.
37. Raung SL, Kuo MD, Wang YM, et al. Role of reactive oxygen intermediates in Japanese encephalitis virus infection in murine neuroblastoma cells. Neuroscience Letters 2001; 315: 9-12.
38. Thongtan T, Cheepsunthorn P, Chaiworakul V, et al. Highly permissive infection of microglial cells by Japanese encephalitis virus: a possible role as a viral reservoir. Microbes and Infection 2010; 12: 37-45. DOI: 10.1016/j.micinf.2009.09.013
39. Yang KD, Yeh WT, Chen RF, et al. A model to study neurotropism and persistency of Japanese encephalitis virus infection in human neuroblastoma cells and leukocytes. Journal of General Virology 2004; 85: 635-642.
40. Lee E, Hall RA, Lobigs M. Common E protein determinants for attenuation of glycosaminoglycan-binding variants of Japanese encephalitis and West Nile viruses. Journal of Virology 2004; 78: 8271-8280. DOI: 10.1128/JVI.78.15.8271-8280.2004
41. Ni H, Barrett AD. Molecular differences between wild-type Japanese encephalitis virus strains of high and low mouse neuroinvasiveness. Journal of General Virology 1996; 77(Pt 7): 1449-1455.
42. Sumiyoshi H, Tignor GH, Shope RE. Characterization of a highly attenuated Japanese encephalitis virus generated from molecularly cloned cDNA. Journal of Infectious Diseases 1995; 171: 1144-1151.
43. Hasegawa H, Yoshida M, Shiosaka T, et al. Mutations in the envelope protein of Japanese encephalitis virus affect entry into cultured cells and virulence in mice. Virology 1992; 191: 158-165.
44. Cecilia D, Gould EA. Nucleotide changes responsible for loss of neuroinvasiveness in Japanese encephalitis virus neutralization-resistant mutants. Virology 1991; 181: 70-77.
45. Zhang Y, Zhang W, Ogata S, et al. Conformational changes of the flavivirus E glycoprotein. Structure 2004; 12: 1607-1618. DOI: 10.1016/j.str.2004.06.019
46. Kim JM, Yun SI, Song BH, et al. A single N-linked glycosylation site in the Japanese encephalitis virus prM protein is critical for cell type-specific prM protein biogenesis, virus particle release, and pathogenicity in mice. Journal of Virology 2008; 82: 7846-7862. DOI: 10.1128/JVI.00789-08
47. Mori Y, Okabayashi T, Yamashita T, et al. Nuclear localization of Japanese encephalitis virus core protein enhances viral replication. Journal of Virology 2005; 79: 3448-3458. DOI: 10.1128/JVI.79.6.3448-3458.2005
48. Melian EB, Hinzman E, Nagasaki T, et al. NS1' of flaviviruses in the Japanese encephalitis virus serogroup is a product of ribosomal frameshifting and plays a role in viral neuroinvasiveness. Journal of Virology 2010; 84: 1641-1647. DOI: 10.1128/JVI.01979-09
49. Gyure KA. West Nile virus infections. Journal of Neuropathology and Experimental Neurology 2009; 68: 1053-1060. DOI: 10.1097/NEN.0b013e3181b88114
50. Kramer LD, Li J, Shi PY. West Nile virus. Lancet Neurology 2007; 6: 171-181. DOI: 10.1016/S1474-4422(07)70030-3
51. Roth D, Henry B, Mak S, et al. West Nile virus range expansion into British Columbia. Emerging Infectious Diseases 2010; 16: 1251-1258.
52. Artsob H, Gubler DJ, Enria DA, et al. West Nile Virus in the New World: trends in the spread and proliferation of West Nile Virus in the Western Hemisphere. Zoonoses and Public Health 2009; 56: 357-369. DOI: 10.1111/j.1863-2378.2008.01207.x
53. Hubalek Z. Mosquito-borne viruses in Europe. Parasitology Research 2008; 103 Suppl 1: S29-43. DOI: 10.1007/s00436-008-1064-7
54. Pauvolid-Correa A, Morales MA, Levis S, et al. Neutralising antibodies for West Nile virus in horses from Brazilian Pantanal. Memórias do Instituto Oswaldo Cruz 2011; 106: 467-474.
55. US Centers for Disease Control and Prevention. [1 February 2011].
56. Diamond MS. Progress on the development of therapeutics against West Nile virus. Antiviral Research 2009; 83: 214-227. DOI: 10.1016/j.antiviral.2009.05.006
57. Sejvar JJ, Davis LE, Szabados E, et al. Delayed-onset and recurrent limb weakness associated with West Nile virus infection. Journal of Neurovirology 2010; 16: 93-100. DOI: 10.3109/13550280903586378
58. Murray K, Walker C, Herrington E, et al. Persistent infection with West Nile virus years after initial infection. Journal of Infectious Diseases 2010; 201: 2-4. DOI: 10.1086/648731
59. Guarner J, Shieh WJ, Hunter S, et al. Clinicopathologic study and laboratory diagnosis of 23 cases with West Nile virus encephalomyelitis. Human Pathology 2004; 35: 983-990.
60. Sampson BA, Armbrustmacher V. West Nile encephalitis: the neuropathology of four fatalities. Annals of the New York Academy of Sciences 2001; 951: 172-178.
61. Shieh WJ, Guarner J, Layton M, et al. The role of pathology in an investigation of an outbreak of West Nile encephalitis in New York, 1999. Emerging Infectious Diseases 2000; 6: 370-372.
62. van Marle G, Antony J, Ostermann H, et al. West Nile virus-induced neuroinflammation: glial infection and capsid protein-mediated neurovirulence. Journal of Virology 2007; 81: 10933-10949. DOI: 10.1128/JVI.02422-06
63. Samuel MA, Diamond MS. Pathogenesis of West Nile Virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion. Journal of Virology 2006; 80: 9349-9360. DOI: 10.1128/JVI.01122-06
64. Kong KF, Delroux K, Wang X, et al. Dysregulation of TLR3 impairs the innate immune response to West Nile virus in the elderly. Journal of Virology 2008; 82: 7613-7623. DOI: 10.1128/JVI.00618-08
65. Wang T, Town T, Alexopoulou L, et al. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nature Medicine 2004; 10: 1366-1373. DOI: 10.1038/nm1140
66. Arjona A, Foellmer HG, Town T, et al. Abrogation of macrophage migration inhibitory factor decreases West Nile virus lethality by limiting viral neuroinvasion. The Journal of Clinical Investigation 2007; 117: 3059-3066. DOI: 10.1172/JCI32218
67. Dai J, Wang P, Bai F, et al. Icam-1 participates in the entry of west nile virus into the central nervous system. Journal of Virology 2008; 82: 4164-4168. DOI: 10.1128/JVI.02621-07
68. Wang P, Dai J, Bai F, et al. Matrix metalloproteinase 9 facilitates West Nile virus entry into the brain. Journal of Virology 2008; 82: 8978-8985. DOI: 10.1128/JVI.00314-08
69. Verma S, Lo Y, Chapagain M, et al. West Nile virus infection modulates human brain microvascular endothelial cells tight junction proteins and cell adhesion molecules: Transmigration across the in vitro blood-brain barrier. Virology 2009; 385: 425-433. DOI: 10.1016/j.virol.2008.11.047
70. Samuel MA, Wang H, Siddharthan V, et al. Axonal transport mediates West Nile virus entry into the central nervous system and induces acute flaccid paralysis. Proceedings of the National Academy of Sciences of the United States of America 2007; 104: 17140-17145. DOI: 10.1073/pnas.0705837104
71. Chu JJ, Ng ML. Characterization of a 105-kDa plasma membrane associated glycoprotein that is involved in West Nile virus binding and infection. Virology 2003; 312: 458-469.
72. Yang MR, Lee SR, Oh W, et al. West Nile virus capsid protein induces p53-mediated apoptosis via the sequestration of HDM2 to the nucleolus. Cellular Microbiology 2008; 10: 165-176. DOI: 10.1111/j.1462-5822.2007.01027.x
73. Samuel MA, Morrey JD, Diamond MS. Caspase 3-dependent cell death of neurons contributes to the pathogenesis of West Nile virus encephalitis. Journal of Virology 2007; 81: 2614-2623. DOI: 10.1128/JVI.02311-06
74. Shrestha B, Gottlieb D, Diamond MS. Infection and injury of neurons by West Nile encephalitis virus. Journal of Virology 2003; 77: 13203-13213.
75. Yang JS, Ramanathan MP, Muthumani K, et al. Induction of inflammation by West Nile virus capsid through the caspase-9 apoptotic pathway. Emerging Infectious Diseases 2002; 8: 1379-1384.
76. King NJ, Getts DR, Getts MT, et al. Immunopathology of flavivirus infections. Immunology and Cell Biology 2007; 85: 33-42. DOI: 10.1038/sj.icb.7100012
77. Getts DR, Terry RL, Getts MT, et al. Ly6c+"inflammatory monocytes" are microglial precursors recruited in a pathogenic manner in West Nile virus encephalitis. The Journal of Experimental Medicine 2008; 205: 2319-2337. DOI: 10.1084/jem.20080421
78. Appler KK, Brown AN, Stewart BS, et al. Persistence of West Nile virus in the central nervous system and periphery of mice. PloS One 2010; 5: e10649. DOI: 10.1371/journal.pone.0010649
79. Siddharthan V, Wang H, Motter NE, et al. Persistent West Nile virus associated with a neurological sequela in hamsters identified by motor unit number estimation. Journal of Virology 2009; 83: 4251-4261. DOI: 10.1128/JVI.00017-09
80. Tesh RB, Siirin M, Guzman H, et al. Persistent West Nile virus infection in the golden hamster: studies on its mechanism and possible implications for other flavivirus infections. Journal of Infectious Diseases 2005; 192: 287-295. DOI: 10.1086/431153
81. Beasley DW, Davis CT, Whiteman M, et al. Molecular determinants of virulence of West Nile virus in North America. Archives of Virology, Supplement 2004; (18): 35-41.
82. Shirato K, Miyoshi H, Goto A, et al. Viral envelope protein glycosylation is a molecular determinant of the neuroinvasiveness of the New York strain of West Nile virus. Journal of General Virology 2004; 85: 3637-3645. DOI: 10.1099/vir.0.80247-0
83. Chambers TJ, Halevy M, Nestorowicz A, et al. West Nile virus envelope proteins: nucleotide sequence analysis of strains differing in mouse neuroinvasiveness. Journal of General Virology 1998; 79(Pt 10): 2375-2380.
84. Botha EM, Markotter W, Wolfaardt M, et al. Genetic determinants of virulence in pathogenic lineage 2 West Nile virus strains. Emerging Infectious Diseases 2008; 14: 222-230.
85. Glass WG, McDermott DH, Lim JK, et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. The Journal of Experimental Medicine 2006; 203: 35-40. DOI: 10.1084/jem.20051970
86. Lim JK, Lisco A, McDermott DH, et al. Genetic variation in OAS1 is a risk factor for initial infection with West Nile virus in man. PLoS Pathogens 2009; 5: e1000321. DOI: 10.1371/journal.ppat.1000321
87. Brien JD, Uhrlaub JL, Hirsch A, et al. Key role of T cell defects in age-related vulnerability to West Nile virus. The Journal of Experimental Medicine 2009; 206: 2735-2745. DOI: 10.1084/jem.20090222
88. World Health Organization. [1 February 2011].
89. US Centers for Disease Control and Prevention. [1 February 2011].
90. Gould EA, Gallian P, De Lamballerie X, et al. First cases of autochthonous dengue fever and chikungunya fever in France: from bad dream to reality! Clinical Microbiology and Infection 2010; 16: 1702-1704. DOI: 10.1111/j.1469-0691.2010.03386.x
91. Halstead SB. Dengue. Lancet 2007; 370: 1644-1652. DOI: 10.1016/S0140-6736(07)61687-0
92. Webster DP, Farrar J, Rowland-Jones S. Progress towards a dengue vaccine. The Lancet Infectious Diseases 2009; 9: 678-687. DOI: 10.1016/S1473-3099(09)70254-3
93. Gulati S, Maheshwari A. Atypical manifestations of dengue. Tropical Medicine & International Health 2007; 12: 1087-1095. DOI: 10.1111/j.1365-3156.2007.01891.x
94. Nogueira RM, Schatzmayr HG, de Filippis AM, et al. Dengue virus type 3, Brazil, 2002. Emerging Infectious Diseases 2005; 11: 1376-1381.
95. Cam BV, Fonsmark L, Hue NB, et al. Prospective case-control study of encephalopathy in children with dengue hemorrhagic fever. The American Journal of Tropical Medicine and Hygiene 2001; 65: 848-851.
96. Pancharoen C, Thisyakorn U. Neurological manifestations in dengue patients. The Southeast Asian Journal of Tropical Medicine and Public Health 2001; 32: 341-345.
97. Thisyakorn U, Thisyakorn C, Limpitikul W, et al. Dengue infection with central nervous system manifestations. The Southeast Asian Journal of Tropical Medicine and Public Health 1999; 30: 504-506.
98. Hendarto SK, Hadinegoro SR. Dengue encephalopathy. Acta Paediatrica Japonica 1992; 34: 350-357.
99. Kumar R, Tripathi S, Tambe JJ, et al. Dengue encephalopathy in children in Northern India: clinical features and comparison with non dengue. Journal of the Neurological Sciences 2008; 269: 41-48. DOI: 10.1016/j.jns.2007.12.018
100. Srey VH, Sadones H, Ong S, et al. Etiology of encephalitis syndrome among hospitalized children and adults in Takeo, Cambodia, 1999-2000. The American Journal of Tropical Medicine and Hygiene 2002; 66: 200-207.
101. Kankirawatana P, Chokephaibulkit K, Puthavathana P, et al. Dengue infection presenting with central nervous system manifestation. Journal of Child Neurology 2000; 15: 544-547.
102. Bhamarapravati N, Tuchinda P, Boonyapaknavik V. Pathology of Thailand haemorrhagic fever: a study of 100 autopsy cases. Annals of Tropical Medicine and Parasitology 1967; 61: 500-510.
103. Chimelli L, Hahn MD, Netto MB, et al. Dengue: neuropathological findings in 5 fatal cases from Brazil. Clinical Neuropathology 1990; 9: 157-162.
104. Domingues RB, Kuster GW, Onuki-Castro FL, et al. Involvement of the central nervous system in patients with dengue virus infection. Journal of the Neurological Sciences 2008; 267: 36-40. DOI: 10.1016/j.jns.2007.09.040
105. Puccioni-Sohler M, Soares CN, Papaiz-Alvarenga R, et al. Neurologic dengue manifestations associated with intrathecal specific immune response. Neurology 2009; 73: 1413-1417. DOI: 10.1212/WNL.0b013e3181bd8258
106. Miagostovich MP, Ramos RG, Nicol AF, et al. Retrospective study on dengue fatal cases. Clinical Neuropathology 1997; 16: 204-208.
107. Balsitis SJ, Coloma J, Castro G, et al. Tropism of dengue virus in mice and humans defined by viral nonstructural protein 3-specific immunostaining. The American Journal of Tropical Medicine and Hygiene 2009; 80: 416-424.
108. de Araujo JM, Schatzmayr HG, de Filippis AM, et al. A retrospective survey of dengue virus infection in fatal cases from an epidemic in Brazil. Journal of Virological Methods 2009; 155: 34-38. DOI: 10.1016/j.jviromet.2008.09.023
109. Nogueira RM, Filippis AM, Coelho JM, et al. Dengue virus infection of the central nervous system (CNS): a case report from Brazil. The Southeast Asian Journal of Tropical Medicine and Public Health 2002; 33: 68-71.
110. Yauch LE, Shresta S. Mouse models of dengue virus infection and disease. Antiviral Research 2008; 80: 87-93. DOI: 10.1016/j.antiviral.2008.06.010
111. Chaturvedi UC, Dhawan R, Khanna M, et al. Breakdown of the blood-brain barrier during dengue virus infection of mice. Journal of General Virology 1991; 72(Pt 4): 859-866.
112. An J, Zhou DS, Kawasaki K, et al. The pathogenesis of spinal cord involvement in dengue virus infection. Virchows Archiv 2003; 442: 472-481. DOI: 10.1007/s00428-003-0785-3
113. Cole GA, Wisseman CL, Jr, Nathanson N. Pathogenesis of type 1 dengue virus infection in suckling, weaning and adult mice. II. Immunofluorescent and histological studies. Journal of Comparative Pathology 1973; 83: 243-252.
114. Sanchez-Burgos G, Hernandez-Pando R, Campbell IL, et al. Cytokine production in brain of mice experimentally infected with dengue virus. Neuroreport 2004; 15: 37-42.
115. Jan JT, Chen BH, Ma SH, et al. Potential dengue virus-triggered apoptotic pathway in human neuroblastoma cells: arachidonic acid, superoxide anion, and NF-kappaB are sequentially involved. Journal of Virology 2000; 74: 8680-8691.
116. Despres P, Frenkiel MP, Ceccaldi PE, et al. Apoptosis in the mouse central nervous system in response to infection with mouse-neurovirulent dengue viruses. Journal of Virology 1998; 72: 823-829.
117. Despres P, Flamand M, Ceccaldi PE, et al. Human isolates of dengue type 1 virus induce apoptosis in mouse neuroblastoma cells. Journal of Virology 1996; 70: 4090-4096.
118. Reyes-Del Valle J, Chavez-Salinas S, Medina F, et al. Heat shock protein 90 and heat shock protein 70 are components of dengue virus receptor complex in human cells. Journal of Virology 2005; 79: 4557-4567. DOI: 10.1128/JVI.79.8.4557-4567.2005
119. Ramos-Castaneda J, Imbert JL, Barron BL, et al. A 65-kDa trypsin-sensible membrane cell protein as a possible receptor for dengue virus in cultured neuroblastoma cells. Journal of Neurovirology 1997; 3: 435-440.
120. Bordignon J, Strottmann DM, Mosimann AL, et al. Dengue neurovirulence in mice: identification of molecular signatures in the E and NS3 helicase domains. Journal of Medical Virology 2007; 79: 1506-1517. DOI: 10.1002/jmv.20958
121. Lee E, Wright PJ, Davidson A, et al. Virulence attenuation of Dengue virus due to augmented glycosaminoglycan-binding affinity and restriction in extraneural dissemination. Journal of General Virology 2006; 87: 2791-2801. DOI: 10.1099/vir.0.82164-0
122. Bray M, Men R, Tokimatsu I, et al. Genetic determinants responsible for acquisition of dengue type 2 virus mouse neurovirulence. Journal of Virology 1998; 72: 1647-1651.
123. Hiramatsu K, Tadano M, Men R, et al. Mutational analysis of a neutralization epitope on the dengue type 2 virus (DEN2) envelope protein: monoclonal antibody resistant DEN2/DEN4 chimeras exhibit reduced mouse neurovirulence. Virology 1996; 224: 437-445. DOI: 10.1006/viro.1996.0550
124. Sanchez IJ, Ruiz BH. A single nucleotide change in the E protein gene of dengue virus 2 Mexican strain affects neurovirulence in mice. Journal of General Virology 1996; 77(Pt 10): 2541-2545.
125. Kawano H, Rostapshov V, Rosen L, et al. Genetic determinants of dengue type 4 virus neurovirulence for mice. Journal of Virology 1993; 67: 6567-6575.
126. Mackenzie JS, Williams DT. The Zoonotic Flaviviruses of Southern, South-Eastern and Eastern Asia, and Australasia: The Potential for Emergent Viruses. Zoonoses and Public Health 2009; DOI: 10.1111/j.1863-2378.2008.01208.x
127. Figueiredo LT. The Brazilian flaviviruses. Microbes and Infection 2000; 2: 1643-1649.
128. Mondini A, Cardeal IL, Lazaro E, et al. Saint Louis encephalitis virus, Brazil. Emerging Infectious Diseases 2007; 13: 176-178.
129. Spinsanti LI, Diaz LA, Glatstein N, et al. Human outbreak of St. Louis encephalitis detected in Argentina, 2005. Journal of Clinical Virology 2008; 42: 27-33. DOI: 10.1016/j.jcv.2007.11.022
130. Mansfield KL, Johnson N, Phipps LP, et al. Tick-borne encephalitis virus - a review of an emerging zoonosis. Journal of General Virology 2009; 90: 1781-1794. DOI: 10.1099/vir.0.011437-0
131. Lindquist L, Vapalahti O. Tick-borne encephalitis. Lancet 2008; 371: 1861-1871. DOI: 10.1016/S0140-6736(08)60800-4
132. Gritsun TS, Lashkevich VA, Gould EA. Tick-borne encephalitis. Antiviral Research 2003; 57: 129-146.
133. Kunze U, ISW. Tick-borne encephalitis: the impact of epidemiology, changing lifestyle, and environmental factors. Conference report of the 12th Annual Meeting of the International Scientific Working Group on Tick-Borne Encephalitis (ISW-TBE). Vaccine 2011; 29: 1355-1356. DOI: 10.1016/j.vaccine.2010.12.048
134. Gritsun TS, Frolova TV, Zhankov AI, et al. Characterization of a siberian virus isolated from a patient with progressive chronic tick-borne encephalitis. Journal of Virology 2003; 77: 25-36.
135. Gelpi E, Preusser M, Garzuly F, et al. Visualization of Central European tick-borne encephalitis infection in fatal human cases. Journal of Neuropathology and Experimental Neurology 2005; 64: 506-512.
136. Mandl CW. Steps of the tick-borne encephalitis virus replication cycle that affect neuropathogenesis. Virus Research 2005; 111: 161-174. DOI: 10.1016/j.virusres.2005.04.007
137. Gaidamovich SY. Tick-Borne Flavivirus Infections. In Exotic Viral Infections, Porterfield JS (eds). Chapman & Hall: London, 1995; 203-221.
138. Ruzek D, Vancova M, Tesarova M, et al. Morphological changes in human neural cells following tick-borne encephalitis virus infection. Journal of General Virology 2009; 90: 1649-1658. DOI: 10.1099/vir.0.010058-0
139. Gelpi E, Preusser M, Laggner U, et al. Inflammatory response in human tick-borne encephalitis: analysis of postmortem brain tissue. Journal of Neurovirology 2006; 12: 322-327. DOI: 10.1080/13550280600848746
140. Ruzek D, Salat J, Palus M, et al. CD8+ T-cells mediate immunopathology in tick-borne encephalitis. Virology 2009; 384: 1-6. DOI: 10.1016/j.virol.2008.11.023
141. Hayasaka D, Nagata N, Fujii Y, et al. Mortality following peripheral infection with tick-borne encephalitis virus results from a combination of central nervous system pathology, systemic inflammatory and stress responses. Virology 2009; 390: 139-150. DOI: 10.1016/j.virol.2009.04.026
142. Kindberg E, Mickiene A, Ax C, et al. A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis. Journal of Infectious Diseases 2008; 197: 266-269. DOI: 10.1086/524709
143. Barkhash AV, Perelygin AA, Babenko VN, et al. Variability in the 2'-5'-oligoadenylate synthetase gene cluster is associated with human predisposition to tick-borne encephalitis virus-induced disease. Journal of Infectious Diseases 2010; 202: 1813-1818. DOI: 10.1086/657418
144. Kindberg E, Vene S, Mickiene A, et al. A functional Toll-like receptor 3 gene (TLR3) may be a risk factor for tick-borne encephalitis virus (TBEV) infection. Journal of Infectious Diseases 2011; 203: 523-528. DOI: 10.1093/infdis/jiq082
145. Naslednikova IO, Ryazantseva NV, Novitskii VV, et al. Chronic tick-borne encephalitis virus antigenemia: possible pathogenesis pathways. Bulletin of Experimental Biology and Medicine 2005; 139: 451-454.
146. Fokina GI, Roikhel VM, Magaznik SS, et al. Development of antibodies to axonal neurofilaments in the progression of chronic tick-borne encephalitis. Acta Virologica 1991; 35: 458-463.
147. Mandl CW, Allison SL, Holzmann H, et al. Attenuation of tick-borne encephalitis virus by structure-based site-specific mutagenesis of a putative flavivirus receptor binding site. Journal of Virology 2000; 74: 9601-9609.
148. Holzmann H, Stiasny K, Ecker M, et al. Characterization of monoclonal antibody-escape mutants of tick-borne encephalitis virus with reduced neuroinvasiveness in mice. Journal of General Virology 1997; 78(Pt 1): 31-37.
149. Holzmann H, Heinz FX, Mandl CW, et al. A single amino acid substitution in envelope protein E of tick-borne encephalitis virus leads to attenuation in the mouse model. Journal of Virology 1990; 64: 5156-5159.
150. Mandl CW, Holzmann H, Meixner T, et al. Spontaneous and engineered deletions in the 3' noncoding region of tick-borne encephalitis virus: construction of highly attenuated mutants of a flavivirus. Journal of Virology 1998; 72: 2132-2140.
151. Ruzek D, Gritsun TS, Forrester NL, et al. Mutations in the NS2B and NS3 genes affect mouse neuroinvasiveness of a Western European field strain of tick-borne encephalitis virus. Virology 2008; 374: 249-255. DOI: 10.1016/j.virol.2008.01.010
152. Ebel GD. Update on Powassan virus: emergence of a North American tick-borne flavivirus. Annual Review of Entomology 2010; 55: 95-110. DOI: 10.1146/annurev-ento-112408-085446
153. Davidson MM, Williams H, Macleod JA. Louping ill in man: a forgotten disease. Journal of Infection 1991; 23: 241-249.
154. Jang H, Boltz DA, Webster RG, et al. Viral parkinsonism. Biochimica et Biophysica Acta 2009; 1792: 714-721. DOI: 10.1016/j.bbadis.2008.08.001
155. Oliphant T, Engle M, Nybakken GE, et al. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nature Medicine 2005; 11: 522-530. DOI: 10.1038/nm1240
156. Morrey JD, Siddharthan V, Wang H, et al. West Nile virus-induced acute flaccid paralysis is prevented by monoclonal antibody treatment when administered after infection of spinal cord neurons. Journal of Neurovirology 2008; 14: 152-163. DOI: 10.1080/13550280801958930
157. Dutta K, Mishra MK, Nazmi A, et al. Minocycline differentially modulates macrophage mediated peripheral immune response following Japanese encephalitis virus infection. Immunobiology 2010; 215: 884-893. DOI: 10.1016/j.imbio.2009.12.003
158. Mishra MK, Dutta K, Saheb SK, et al. Understanding the molecular mechanism of blood-brain barrier damage in an experimental model of Japanese encephalitis: correlation with minocycline administration as a therapeutic agent. Neurochemistry International 2009; 55: 717-723. DOI: 10.1016/j.neuint.2009.07.006
159. Mishra MK, Basu A. Minocycline neuroprotects, reduces microglial activation, inhibits caspase 3 induction, and viral replication following Japanese encephalitis. Journal of Neurochemistry 2008; 105: 1582-1595. DOI: 10.1111/j.1471-4159.2008.05238.x
160. Michaelis M, Kleinschmidt MC, Doerr HW, et al. Minocycline inhibits West Nile virus replication and apoptosis in human neuronal cells. Journal of Antimicrobial Chemotherapy 2007; 60: 981-986. DOI: 10.1093/jac/dkm307